---
title: "Ab&B Bio-Tech Strengthens Board With New Independent Director Nomination"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284023009.md"
description: "Ab&B Bio-Tech CO., LTD. has nominated Ms. Lui Mei Ka as an independent non-executive director, pending shareholder approval. This appointment aims to enhance corporate governance following the departure of Mr. Cheng Qianwen. Ms. Lui brings extensive experience in financial management and compliance within Hong Kong-listed firms. Ab&B Bio-Tech, listed on the Hong Kong Stock Exchange, focuses on biopharmaceutical research and technologies in the life sciences sector, with a market cap of HK$11.54B."
datetime: "2026-04-24T14:40:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284023009.md)
  - [en](https://longbridge.com/en/news/284023009.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284023009.md)
---

# Ab&B Bio-Tech Strengthens Board With New Independent Director Nomination

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest update is out from Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ).

Ab&B Bio-Tech has nominated seasoned finance professional Ms. Lui Mei Ka as an independent non-executive director for its second board session, with her appointment also including a role on the audit committee, subject to shareholder approval and related amendments to the company’s articles of association. The move follows the pending departure of non-executive director and audit committee member Mr. Cheng Qianwen, and is expected to strengthen the company’s corporate governance with Ms. Lui’s extensive background in financial management, listed company oversight, and compliance across multiple Hong Kong-listed firms.

**More about Ab&B Bio-Tech CO., LTD. JS Class H**

Ab&B Bio-Tech CO., LTD. JS is a biotechnology company based in the People’s Republic of China, listed on the Hong Kong Stock Exchange. The group focuses on biopharmaceutical research and related technologies, positioning itself within the broader life sciences and healthcare sector and serving both domestic and international markets.

**Average Trading Volume:** 793,219

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$11.54B

Learn more about 2627 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02627.HK](https://longbridge.com/en/quote/02627.HK.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)

## Related News & Research

- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [Ab&B Bio-Tech Calls 2026 EGM to Overhaul Governance and Appoint New Auditor](https://longbridge.com/en/news/285581318.md)
- [16:52 ETNexusTek Named a Contender in ISG Provider Lens® Life Sciences Digital Services 2026 Report](https://longbridge.com/en/news/286818120.md)
- [12:27 ETBioSpace Wins Several Accolades for Biopharma Journalism, Including 2026 Neal and Azbee National Gold Awards](https://longbridge.com/en/news/286593464.md)
- [Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 | WVE Stock News](https://longbridge.com/en/news/286925108.md)